Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CIITA Double Nickase Plasmid (h): sc-401762-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CIITA Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CIITA Double Nickase Plasmid (h) and CIITA Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CIITA. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CIITA Antibody (7-1H): sc-13556
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CIITA Double Nickase Plasmid (h) | sc-401762-NIC | 20 µg | $410.00 | |||
CIITA Double Nickase Plasmid (h2) | sc-401762-NIC-2 | 20 µg | $410.00 |
CIITA (class II major histocompatibility complex transactivator) is a master regulator of MHC class II gene expression in antigen-presenting cells, coordinating transcription of HLA-DP, HLA-DQ, and HLA-DR loci. Acting as a non–DNA-binding coactivator, CIITA integrates signals from interferon-γ and other inflammatory pathways to assemble enhanceosomes with factors such as RFX and NF-Y and to recruit chromatin-modifying machinery. Through control of antigen processing and presentation programs, CIITA shapes CD4+ T cell priming and immune surveillance, and altered CIITA activity has been linked to immune dysregulation and tumor immune evasion. Dysregulated CIITA-dependent transcriptional networks are also studied in the context of inflammatory and autoimmune phenotypes and host–pathogen interactions.
CIITA Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CIITA locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CIITA. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CIITA function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CIITA-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.